Skip Navigation


Carcinogenesis Advance Access originally published online on December 3, 2004
Carcinogenesis 2005 26(3):621-629; doi:10.1093/carcin/bgh348
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
26/3/621    most recent
bgh348v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by von Weymarn, L. B.
Right arrow Articles by Hollenberg, P. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by von Weymarn, L. B.
Right arrow Articles by Hollenberg, P. F.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis vol.26 no.3 © Oxford University Press 2004; all rights reserved.

ARTICLE

Effects of 8-methoxypsoralen on cytochrome P450 2A13

Linda B. von Weymarn1, Qing-Yu Zhang2, Xinxin Ding2 and Paul F. Hollenberg1,3

1 Department of Pharmacology, University of Michigan, Ann Arbor, Michigan, USA and 2 Wadsworth Center, New York State Department of Health, Albany, New York, USA

3 To whom correspondence should be addressed Email: phollen{at}umich.edu

Cytochrome P450 2A13 efficiently catalyzes the bioactivation of several tobacco-specific nitrosamines in vitro. This efficient bioactivation together with the selective expression of P450 2A13 in the human lung suggests that this P450 may play an important role in the initiation of lung cancer in smokers. Therefore, the identification of potent and selective inhibitors/inactivators of P450 2A13 could potentially help to lower the risk of lung cancer in smokers. In this study, we investigated the ability of 8-methoxypsoralen (8-MOP), a known inhibitor of P450 2A6, to inhibit and inactivate the activities of heterologously expressed P450 2A13 in reconstituted systems. We found that 8-MOP is a potent inhibitor of P450 2A13-mediated metabolism of several compounds, including testosterone, which had not been known to be a P450 2A13 substrate. The KI for the non-competitive inhibition of P450 2A13-mediated coumarin 7-hydroxylation by 8-MOP was 0.11 µM. The inhibition of P450 2A13 was accompanied by inactivation of the enzyme. Therefore, the observed decrease in activity is most likely due to the inactivation of the enzyme together with competitive or non-competitive inhibition of P450 2A13 by 8-MOP. The inactivation did not result in a loss of native heme, or a significant change in the reduced-CO spectrum of the P450, and did not generate any detectable heme adducts. Instead, the inactivation of P450 2A13 by8-MOP occurred through the formation of an adduct to the apoprotein. LC/MS analysis of the adducted protein indicated an increase in the mass of 232 Da compared with the unadducted protein. This mass shift correlates with the addition of one molecule of 8-MOP plus one atom of oxygen atom to the P450 apoprotein.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
X. Zhang, J. D'Agostino, H. Wu, Q.-Y. Zhang, L. von Weymarn, S. E. Murphy, and X. Ding
CYP2A13: Variable Expression and Role in Human Lung Microsomal Metabolic Activation of the Tobacco-Specific Carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone
J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 570 - 578.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
P. J. Brown, L. L. Bedard, K. R. Reid, D. Petsikas, and T. E. Massey
Analysis of CYP2A Contributions to Metabolism of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone in Human Peripheral Lung Microsomes
Drug Metab. Dispos., November 1, 2007; 35(11): 2086 - 2094.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
S.-L. Wang, X.-Y. He, J. Shen, J.-S. Wang, and J.-Y. Hong
The Missense Genetic Polymorphisms of Human CYP2A13: Functional Significance in Carcinogen Activation and Identification of A Null Allelic Variant
Toxicol. Sci., November 1, 2006; 94(1): 38 - 45.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
L. B. von Weymarn, J. A. Chun, and P. F. Hollenberg
Effects of benzyl and phenethyl isothiocyanate on P450s 2A6 and 2A13: potential for chemoprevention in smokers
Carcinogenesis, April 1, 2006; 27(4): 782 - 790.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
L. B. von Weymarn, K. M. Brown, and S. E. Murphy
Inactivation of CYP2A6 and CYP2A13 during Nicotine Metabolism
J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 295 - 303.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.